XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

This study is testing a combination of drugs — XELOX (capecitabine + oxaliplatin), fruquintinib (a drug that blocks tumor blood vessel growth), and sintilimab (an immunotherapy drug) — as a 'conversion therapy' for people with advanced stomach or gastroesophageal junction cancer that has spread only to the liver and/or specific abdominal lymph nodes. The aim is to shrink the cancer enough that surgery becomes possible. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed HER2-negative stomach or gastroesophageal junction adenocarcinoma - Your cancer has spread only to the liver (5 or fewer lesions, each under 5 cm) and/or to specific nearby lymph nodes (retroperitoneal) - You have at least one measurable tumor on imaging - You have not previously received VEGFR-targeted drugs or PD-1/PD-L1 immunotherapy **You may NOT be eligible if...** - Your cancer has spread to other distant organs beyond the liver and retroperitoneal lymph nodes - You have more than 5 liver metastases or a single lesion larger than 5 cm - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.